Back to top

Raymond James Reaffirms Their Buy Rating on Dyne Therapeutics (DYN)

In a report released yesterday, Martin Auster from Raymond James maintained a Buy rating on Dyne Therapeutics, with a price target of $40.00. The c...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Dyne Therapeutics, Inc. (DYN)